Search

Author/Creator Antonia, Scott

11. Development of MEDI4736, an anti-programmed cell death ligand 1 (PD-L1) antibody, as monotherapy or in combination with other therapies in the treatment of non-small cell lung cancer (NSCLC). (6th November 2014)

Authors:
Brahmer, Julie; Balmanoukian, Ani; Goldberg, Sarah; Ou, Sai-Hong; Blake-Haskins, Andrew; Karakunnel, Joyson; Stockman, Paul; Rizvi, Naiyer; Antonia, Scott
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 2(2014)Supplement 3
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

12. Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial. Issue 4 (12th April 2022)

Authors:
Aggarwal, Charu; Prawira, Amy; Antonia, Scott; Rahma, Osama; Tolcher, Anthony; Cohen, Roger B; Lou, Yanyan; Hauke, Ralph; Vogelzang, Nicholas; P Zandberg, Dan; Kalebasty, Arash Rezazadeh; Atkinson, Victoria; Adjei, Alex A; Seetharam, Mahesh; Birnbaum, Ariel; Weickhardt, Andrew; Ganju, Vinod; Josh...
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 10:Issue 4(2022)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

13. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Issue 10272 (30th January 2021)

Authors:
Baas, Paul; Scherpereel, Arnaud; Nowak, Anna K; Fujimoto, Nobukazu; Peters, Solange; Tsao, Anne S; Mansfield, Aaron S; Popat, Sanjay; Jahan, Thierry; Antonia, Scott; Oulkhouir, Youssef; Bautista, Yolanda; Cornelissen, Robin; Greillier, Laurent; Grossi, Francesco; Kowalski, Dariusz; Rodríguez-Cid,...
Journal:
Lancet
Issue:
Volume 397:Issue 10272(2021)
Page Start:
375
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

14. First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743. (May 2022)

Authors:
Scherpereel, Arnaud; Antonia, Scott; Bautista, Yolanda; Grossi, Francesco; Kowalski, Dariusz; Zalcman, Gérard; Nowak, Anna K.; Fujimoto, Nobukazu; Peters, Solange; Tsao, Anne S.; Mansfield, Aaron S.; Popat, Sanjay; Sun, Xiaowu; Lawrance, Rachael; Zhang, Xiaoqing; Daumont, Melinda J.; Bennett, Bry...
Journal:
Lung cancer
Issue:
Volume 167(2022)
Page Start:
8
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

15. Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer. Issue 7 (1st March 2021)

Authors:
Borghaei, Hossein; Gettinger, Scott; Vokes, Everett E.; Chow, Laura Q. M.; Burgio, Marco Angelo; de Castro Carpeno, Javier; Pluzanski, Adam; Arrieta, Oscar; Frontera, Osvaldo Arén; Chiari, Rita; Butts, Charles; Wójcik-Tomaszewska, Joanna; Coudert, Bruno; Garassino, Marina Chiara; Ready, Neal; Fel...
Journal:
Journal of clinical oncology
Issue:
Volume 39:Issue 7(2021)
Page Start:
723
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

18. Patient-Reported Distress and Clinical Outcomes with Immuno-Oncology Agents in Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Real-World Retrospective Cohort Study. (January 2023)

Authors:
Bodd, Monica H.; Locke, Susan C.; Wolf, Steve P.; Antonia, Scott; Crawford, Jeffrey; Hartman, John; Herring, Kris W.; Ready, Neal E.; Stinchcombe, Thomas E.; Troy, Jesse D.; Williams, Chakita; Clarke, Jeffrey M.; LeBlanc, Thomas W.
Journal:
Lung cancer
Issue:
Volume 175(2023)
Page Start:
17
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

19. Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032. (4th November 2015)

Authors:
Taylor, Matthew; Antonia, Scott; Bendell, Johanna; Calvo, Emiliano; Jäger, Dirk; de Braud, Filippo; Ott, Patrick A; Pietanza, M Catherine; Horn, Leora; Le, Dung T; Morse, Michael A; López-Martin, José A; Ascierto, Paolo A; Christensen, Olaf; Simon, Jason S; Lin, Chen-Sheng; Eder, Joseph Paul
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 3(2015)Supplement 2
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

20. Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032. Issue 2 (December 2015)

Authors:
Taylor, Matthew; Antonia, Scott; Bendell, Johanna; Calvo, Emiliano; Jäger, Dirk; de Braud, Filippo; Ott, Patrick; Pietanza, M; Horn, Leora; Le, Dung; Morse, Michael; López-Martin, José; Ascierto, Paolo; Christensen, Olaf; Simon, Jason; Lin, Chen-Sheng; Eder, Joseph
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 3:Issue 2(2015)
Page Start:
1
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗